Ilaris, from Novartis, approved in the US for new indication – juvenile arthritis

May 10, 2013 | By Márcio Barra

Yet another approval for Ilaris

Back in March 2013, Novartis saw their rare disease drug Ilaris receiving positive opinion from the CHMP and the European Commission for the treatment of patients with frequent attacks of acute gouty arthritis. Today, Ilaris received approval for yet another rare indication, this time from the FDA, for the treatment Systemic juvenile idiopathic arthritis, the most common form of arthritis in children and adolescents. FDA’s approval makes Ilaris the only treatment for juvenile idiopathic arthritis that can be given as a monthly subcutaneous injection. The approval was based on two Phase III trials in SJIA patients, aged 2–19.

Ilaris, or canakinumab, was approved back in 2009 by the FDA and EMA for the treatment of cryopyrin-associated periodic syndromes, or CAPS, a suite of rare (7,000 people worldwide), life-long, genetic autoinflammatory diseases including familial cold autoinflammatory syndrome, Muckle–Wells syndrome and others. Ilaris is a biologic. More specifically a selective, fully human, monoclonal antibody that inhibits IL-1 beta, a part of the body’s immune system defenses that, when over expressed, leads to inflammation.

Novartis strategy of betting for new indications for its orphan drugs is definitely paying off, and if Ilaris keeps this positive momentum going, blockbuster status is inbound.



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: